Current FDA-approved therapeutic options for patients with metastatic melanoma include dacarbazine, interleukin 2, ipilimumab, vemurafenib, dabrafenib, and trametinib, but long-term tumor regression using available agents remains out of reach for most patients. Adoptive cell transfer (ACT) with autologous tumor-infiltrating lymphocytes (TILs) has shown encouraging results in clinical trials, with evidence of durable ongoing complete responses in patients with advanced melanoma. Emerging techniques to engineer T-cell receptors (TCRs) or chimeric antigen receptors (CARs) using lymphocytes from peripheral blood may offer new tactics in ACT.
Methods
We reviewed the literature to provide a synopsis on the development and clinical trial results of ACT, as well as the future outlook for using ACT in patients with metastatic melanoma.
Results
ACT with TILs as part of a lymphodepleting regimen has been shown in clinical trials to cause objective clinical responses in approximately 40% to 72% of patients with metastatic melanoma, with up to 40% of those patients experiencing complete responses lasting up to 7 years ongoing. Pilot trials using TCR-engineered cells against melanoma-associated antigens MART-1 and gp100 and the cancer-testis antigen NY-ESO-1 have shown clinical responses in patients with melanoma. CAR cells directed against melanoma have been tested only in preclinical models; however, CAR cells targeting other histologies such as lymphoma have elicited antitumor responses in patients.
Conclusions
An example of state-of-the-art personalized medicine, ACT is a potentially curative therapy for patients with metastatic melanoma. Ongoing trials aiming to simplify the regimens may allow a broader range of patients to be treated and enable ACT to be offered by academic cancer centers.
References
1.
HodiF.S., O'DayS.J., McDermottD.F.. Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med.2010; 363(8): 711–723.
2.
SondakV.K., SabelM.S., MuléJ.J.. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?Clin Cancer Res.2006; 12(7 Pt 2): 2337s–2341s.
3.
Chur chS.E., JensenS.M., TwittyC.G.. Multiple vaccinations: friend or foe.Cancer J.2011; 17(5): 379–396.
4.
RosenbergS.A., YangJ.C., RestifoN.P.. Cancer immunotherapy: moving beyond current vaccines.Nat Med.2004; 10(9): 909–915.
5.
RosenbergS.A., SherryR.M., MortonK.E.. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.J Immunol.2005; 175(9): 6169–6176.
6.
AtkinsM.B., LotzeM.T., DutcherJ.P.. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.J Clin Oncol.1999; 17(7): 2105–2116.
PrietoP.A., YangJ.C., SherryR.M.. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.Clin Cancer Res.2012; 18(7): 2039–2047.
9.
TopalianS.L., HodiF.S., BrahmerJ.R.. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med.2012; 366(26): 2443–2454.
10.
HamidO., RobertC., DaudA.. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.N Engl J Med.2013; 369(2): 134–144.
11.
BrahmerJ.R., TykodiS.S., ChowL.Q.. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.N Engl J Med.2012; 366(26): 2455–2465.
12.
WolchokJ.D., KlugerH., CallahanM.K.. Nivolumab plus ipilimumab in advanced melanoma.N Engl J Med.2013; 369(2): 122–133.
13.
RosenbergS.A., YangJ.C., SherryR.M.. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.Clin Cancer Res.2011; 17(13): 4550–4557.
14.
MaccartyW.C.. Factors which influence longevity in cancer: a study of 293 cases.Ann Surg.1922; 76(1): 9–12.
15.
BillinghamR.E., BrentL., MedawarP.B.. Quantitative studies on tissue transplantation immunity. II. The origin, strength and duration of actively and adoptively acquired immunity.Proc R Soc Lond B Biol Sci.1954; 143(910): 58–80.
16.
MorganD.A., RuscettiF.W., GalloR.. Selective in vitro growth of T lymphocytes from normal human bone marrows.Science.1976; 193(4257): 1007–1008.
17.
SmithK.A., LachmanL.B., OppenheimJ.J.. The functional relationship of the interleukins.J Exp Med.1980; 151(6): 1551–1556.
18.
SmithK.A., GilbrideK.J., FavataM.F.. Lymphocyte activating factor promotes T-cell growth factor production by cloned murine lymphoma cells.Nature.1980; 287(5785): 853–855.
19.
RosenbergS.A., GrimmE.A., McGroganM.. Biological activity of recombinant human interleukin-2 produced in Escherichia coli.Science.1984; 223(4643): 1412–1414.
20.
RosenbergS.A., LotzeM.T., MuulL.M.. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.N Engl J Med.1985; 313(23): 1485–1492.
21.
RosenbergS.A., LotzeM.T., YangJ.C.. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.J Natl Cancer Inst.1993; 85(8): 622–632.
22.
RosenbergS.A., SpiessP., LafreniereR.. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.Science.1986; 233(4770): 1318–1321.
23.
MuulL.M., SpiessP.J., DirectorE.P.. Identification of specific cyto-lytic immune responses against autologous tumor in humans bearing malignant melanoma.J Immunol.1987; 138(3): 989–995.
24.
TopalianS.L., SolomonD., AvisF.P.. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.J Clin Oncol.1988; 6(5): 839–853.
25.
GoffS.L., SmithF.O., KlapperJ.A.. Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL.J Immunother.2010; 33(8): 840–847.
26.
RosenbergS.A., PackardB.S., AebersoldP.M.. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.N Engl J Med.1988; 319(25): 1676–1680.
27.
PhanG.Q., AttiaP., SteinbergS.M.. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.J Clin Oncol.2001; 19(15): 3477–3482.
28.
SchwartzentruberD.J.. Guidelines for the safe administration of high-dose interleukin-2.J Immunother.2001; 24(4): 287–293.
29.
RosenbergS.A., YannelliJ.R., YangJ.C.. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.J Natl Cancer Inst.1994; 86(15): 1159–1166.
30.
GattinoniL., FinkelsteinS.E., KlebanoffC.A.. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.J Exp Med.2005; 202(7): 907–912.
31.
WrzesinskiC., RestifoN.P.. Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based antitumor immunotherapy.Curr Opin Immunol.2005; 17(2): 195–201.
32.
DudleyM.E., YangJ.C., SherryR.. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.J Clin Oncol.2008; 26(32): 5233–5239.
33.
ChildsR., ChernoffA., ContentinN.. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.N Engl J Med.2000; 343(11): 750–758.
34.
TherasseP., ArbuckS.G., EisenhauerE.A.. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors.J Natl Cancer Inst.2000; 92(3): 205–216.
35.
DudleyM.E., WunderlichJ.R., YangJ.C.. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.J Clin Oncol.2005; 23(10): 2346–2357.
36.
HongJ.J., RosenbergS.A., DudleyM.E.. Successful treatment of melanoma brain metastases with adoptive cell therapy.Clin Cancer Res.2010; 16(19): 4892–4898.
37.
ZhouJ., ShenX., HuangJ.. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.J Immunol.2005; 175(10): 7046–7052.
38.
HuangJ., KhongH.T., DudleyM.E.. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression.J Immunother.2005; 28(3): 258–267.
39.
HuangJ., KerstannK.W., AhmadzadehM.. Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy.J Immunol.2006; 176(12): 7726–7735.
DudleyM.E., GrossC.A., LanghanM.M.. CD8+ enriched “young” tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.Clin Cancer Res.2010; 16(24): 6122–6131.
42.
BesserM.J., Shapira-FrommerR., TrevesA.J.. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.Clin Cancer Res.2010; 16(9): 2646–2655.
43.
ItzhakiO., HovavE., ZiporenY.. Establishment and large-scale expansion of minimally cultured “young” tumor infiltrating lymphocytes for adoptive transfer therapy.J Immunother.2011; 34(2): 212–220.
44.
Pilon-ThomasS., KuhnL., EllwangerS.. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.J Immunother.2012; 35(8): 615–620.
45.
UllenhagG.J., SadeghiA.M., CarlssonB.. Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy.Cancer Immunol Immunother.2012; 61(5): 725–732.
46.
JosephR.W., PeddareddigariV.R., LiuP.. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy.Clin Cancer Res.2011; 17(14): 4882–4891.
47.
EllebaekE., IversenT.Z., JunkerN.. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients.J Transl Med.2012; 10: 169.
48.
SadelainM., RiviereI., BrentjensR.. Targeting tumours with genetically enhanced T lymphocytes.Nat Rev Cancer.2003; 3(1): 35–45.
49.
ParkT.S., RosenbergS.A., MorganR.A.. Treating cancer with genetically engineered T cells.Trends Biotechnol.2011; 29(11): 550–557.
50.
MorganR.A., DudleyM.E., WunderlichJ.R.. Cancer regression in patients after transfer of genetically engineered lymphocytes.Science.2006; 314(5796): 126–129.
51.
JohnsonL.A., MorganR.A., DudleyM.E.. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.Blood.2009; 114(3): 535–546.
52.
ParkhurstM.R., YangJ.C., LanganR.C.. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.Mol Ther.2011; 19(3): 620–626.
53.
RobbinsP.F., MorganR.A., FeldmanS.A.. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.J Clin Oncol.2011; 29(7): 917–924.
54.
LoA.S., MaQ., LiuD.L.. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors.Clin Cancer Res.2010; 16(10): 2769–2780.
55.
YvonE., Del VecchioM., SavoldoB.. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells.Clin Cancer Res.2009; 15(18): 5852–5860.
56.
BurnsW.R., ZhaoY., FrankelT.L.. A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas.Cancer Res.2010; 70(8): 3027–3033.
57.
PuleM.A., SavoldoB., MyersG.D.. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.Nat Med.2008; 14(11): 1264–1270.
58.
UckunF.M., JaszczW., AmbrusJ.L.. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins.Blood.1988; 71(1): 13–29.
59.
KochenderferJ.N., WilsonW.H., JanikJ.E.. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.Blood.2010; 116(20): 4099–4102.
60.
KochenderferJ.N., DudleyM.E., FeldmanS.A.. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.Blood.2012; 119(12): 2709–2720.
61.
PorterD.L., LevineB.L., KalosM.. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.N Engl J Med.2011; 365(8): 725–733.
62.
BrentjensR., YehR., BernalY.. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.Mol Ther.2010; 18(4): 666–668.
63.
MorganR.A., YangJ.C., KitanoM.. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.Mol Ther.2010; 18(4): 843–851.
64.
BalchC.M., GershenwaldJ.E., SoongS.J.. Final version of 2009 AJCC melanoma staging and classification.J Clin Oncol.2009; 27(36): 6199–6206.
65.
KerkarS.P., MuranskiP., KaiserA.. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.Cancer Res.2010; 70(17): 6725–6734.
66.
ZhangL., KerkarS.P., YuZ.. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.Mol Ther.2011; 19(4): 751–759.
